Document Type


Publication Date


Academic Year



Introduction: Kidney transplant recipients are often on anticoagulation or antiplatelet therapy, for a variety of indications. These medications are associated with increased risk of bleeding but may reduce risk of thrombosis and possible complications such as allograft loss. The aim of our study is to evaluate the effect of perioperative anticoagulation or antiplatelet therapy on patient and allograft outcomes.

Methods: Data collection was done by retrospective chart review of all patients who underwent a kidney or kidney/pancreas transplantation at Thomas Jefferson University Hospital (TJUH) from 2012-2019. We recorded perioperative anticoagulation and antiplatelet therapy, risk factors for bleeding and thrombosis, post-transplant episodes of bleeding or thrombosis, allograft function at multiple timepoints from 30 days to 3 years post-transplant, allograft loss, and mortality. Data analysis will evaluate relative outcomes based on perioperative anticoagulation or antiplatelet status.

Results: We have completed collecting data for the 872 kidney or kidney/pancreas transplants done at TJUH from 2012-2019 and are currently working on analyzing the data. The patients will be evaluated in groups based on the presence and type of anticoagulation or antiplatelet therapy. These groups will then be compared based on patient and allograft outcomes.

Discussion: We expect to find that patients on perioperative anticoagulation or antiplatelet therapy had higher rates and severity of bleeding, but lower rates of thrombosis and therefore allograft loss and mortality. This study will improve our understanding of perioperative anticoagulation and antiplatelet therapy so we may develop treatment guidelines for the TJUH kidney transplant program.